Carvajal RD, et al. - Selumetinib (AZD6244, ARRY-142886) is an oral, potent, and selective MEK1/2 inhibitor with a short half-life, which demonstrated single-agent activity in patients with metastatic uveal melanoma in a randomized phase II trial. In this current phase III, double-blind trial, it was demonstrated that selumetinib + dacarbazine, when compared with placebo + dacarbazine, did not significantly improve progression-free survival but had a tolerable safety profile in patients with metastatic uveal melanoma.